Novel Gemini vitamin D3 analogs have potent antitumor activity

Journal of Steroid Biochemistry and Molecular Biology

Volumn 112, Issue 1-3, 2008, Pages 151-156

  Saito, Tsuyako ^a   Okamoto, Ryoko ^a   Haritunians, Talin ^a   O'Kelly, James ^a   Uskokovic, Milan ^b   Maehr, Hubert ^b   Marczak, Stanislaw ^b   Jankowski, Pawel ^b   Badr, Riem ^a   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Antitumor; Deuterated Gemini vitamin D3; Vitamin D

Indexed keywords

BXL 010098; BXL 010108; BXL 010114; BXL 010117; BXL 010120; CALCITRIOL; COLECALCIFEROL DERIVATIVE; LIPOCORTIN 5; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLECALCIFEROL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS;

EID: 55349142822     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.09.012     Document Type: Article

References (26)

1. Schwaller J., Koeffler H.P., Niklaus G., Loetscher P., Nagel S., Fey M.F., and Tobler A. Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells. J. Clin. Invest. 95 (1995) 973-979
2. 3 in HL60 cells. Cancer Res. 56 (1996) 264-267
3. 3 analog (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res. 56 (1996) 3570-3576
4. Grillier I., Umiel T., Elstner E., Collins S.J., and Koeffler H.P. Alterations of differentiation, clonal proliferation, cell cycle progression and bcl-2 expression in RAR alpha-altered sublines of HL-60. Leukemia 11 (1997) 393-400
5. 3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat. Rep. 69 (1985) 1399-1407
6. 3 and its fluorinated analogues. Cancer Res. 44 (1984) 5624-5628
7. Spina C., Tangpricha V., Yao M., Zhou W., Wolfe M.M., Maehr H., Uskokovic M., Adorini L., and Holick M.F. Colon cancer and solar ultraviolet B radiation and prevention and treatment of colon cancer in mice with vitamin D and its Gemini analogs. J. Steroid Biochem. Mol. Biol. 97 (2005) 111-120
8. 3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. Cancer Res. 50 (1990) 6857-6864
9. Spina C.S., Ton L., Yao M., Maehr H., Wolfe M.M., Uskokovic M., Adorini L., and Holick M.F. Selective vitamin D receptor modulators and their effects on colorectal tumor growth. J. Steroid Biochem. Mol. Biol. 103 (2007) 757-762
10. Munker R., Kobayashi T., Elstner E., Norman A.W., Uskokovic M., Zhang W., Andreeff M., and Koeffler H.P. A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 88 (1996) 2201-2209
11. Spina C.S., Tangpricha V., Uskokovic M., Adorinic L., Maehr H., and Holick M.F. Vitamin D and cancer. Anticancer Res. 26 (2006) 2515-2524
12. 3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway. J. Steroid Biochem. Mol. Biol. 100 (2006) 107-116
13. Lee H.J., Liu H., Goodman C., Ji Y., Maehr H., Uskokovic M., Notterman D., Reiss M., and Suh N. Gene expression profiling changes induced by a novel Gemini vitamin D derivative during the progression of breast cancer. Biochem. Pharmacol. 72 (2006) 332-343
14. Hisatake J., O'Kelly J., Uskokovic M.R., Tomoyasu S., and Koeffler H.P. Novel vitamin D(3) analog, 21-(3-methyl-3-hydroxy-butyl)-19-nor D(3), that modulates cell growth, differentiation, apoptosis, cell cycle, and induction of PTEN in leukemic cells. Blood 97 (2001) 2427-2433
15. Gaddipati J.P., McLeod D.G., Sesterhenn I.A., Hussussian C.J., Tong Y.A., Seth P., Dracopoli N.C., Moul J.W., and Srivastava S. Mutations of the p16 gene product are rare in prostate cancer. Prostate 30 (1997) 188-194
16. Isaacs W.B., Carter B.S., and Ewing C.M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 51 (1991) 4716-4720
17. Welsh J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem. Cell Biol. 72 (1994) 537-545
18. 3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: possible implication of intracellular calcium. Cancer Lett. 97 (1995) 99-106
19. Mathiasen I.S., Lademann U., and Jaattela M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res. 59 (1999) 4848-4856
20. Norman A.W., Manchand P.S., Uskokovic M.R., Okamura W.H., Takeuchi J.A., Bishop J.E., Hisatake J.I., Koeffler H.P., and Peleg S. Characterization of a novel analogue of 1alpha,25(OH)(2)-vitamin D(3) with two side chains: interaction with its nuclear receptor and cellular actions. J. Med. Chem. 43 (2000) 2719-2730
21. Uskokovic M.R., Norman A.W., Manchand P.S., Studzinski G.P., Campbell M.J., Koeffler H.P., Takeuchi A., Siu-Caldera M.L., Rao D.S., and Reddy G.S. Highly active analogs of 1alpha,25-dihydroxyvitamin D(3) that resist metabolism through C-24 oxidation and C-3 epimerization pathways. Steroids 66 (2001) 463-471
22. 3. Biochem. Pharmacol. 45 (1993) 2331-2336
23. Halloran B.P., Bikle D.D., Castro M.E., and Gee E. Isotopic labeling affects 1,25-dihydroxyvitamin D metabolism. Biochemistry 28 (1989) 1278-1281
24. Beer T.M., Munar M., and Henner W.D. A Phase I trial of pulse calcitriol in patients with refractory malignancies. Cancer 91 (2001) 2431-2439
25. Trump D.L., Hershberger P.A., Bernardi R.J., Ahmed S., Muindi J., Fakih M., Yu W.D., and Johnson C.S. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J. Steroid Biochem. Mol. Biol. 89-90 (2004) 519-526
26. Luong Q.T., and Koeffler H.P. Vitamin D compounds in leukemia. J. Steroid Biochem. Mol. Biol. 97 (2005) 195-202